Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
17
CLRB Quote, Financials, Valuation and Earnings
Last price:
$3.16
Seasonality move
:
3.11%
Day range:
$2.85 - $3.13
52-week range:
$2.45 - $20.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
137.94x
P/B ratio:
0.74x
Volume:
46.1K
Avg. volume:
100.3K
1-year change:
-63.29%
Market cap:
$5.5M
Revenue:
--
EPS (TTM):
-$6.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
-- | -$1.22 | -- | -20.45% | $47.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 110.49% | -58.59% | $479.79 |
|
IMNN
Imunon, Inc.
|
-- | -$1.82 | -- | -269.06% | $21.50 |
|
PAVM
PAVmed, Inc.
|
-- | -$4.50 | -100% | -78.99% | $9.50 |
|
PDSB
PDS Biotechnology Corp.
|
-- | -$0.20 | -- | -4.94% | $7.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
$3.04 | $47.00 | $5.5M | -- | $0.00 | 0% | 137.94x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.56 | $31.21 | $4B | 15.16x | $0.00 | 0% | 3.79x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$328.16 | $479.79 | $43.4B | 1,364.49x | $0.00 | 0% | 13.46x |
|
IMNN
Imunon, Inc.
|
$3.27 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
PAVM
PAVmed, Inc.
|
$10.80 | $9.50 | $10M | 0.30x | $0.00 | 0% | 5,045.37x |
|
PDSB
PDS Biotechnology Corp.
|
$0.72 | $7.50 | $39.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
4.4% | -0.908 | 3.58% | 2.56x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.064 | 4.61% | 2.37x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
PAVM
PAVmed, Inc.
|
20.6% | -0.669 | 34.03% | 0.30x |
|
PDSB
PDS Biotechnology Corp.
|
65.52% | 0.267 | 37.29% | 1.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CLRB
Cellectar Biosciences, Inc.
|
-$52.3K | -$4.9M | -154.34% | -160.56% | -- | -$4.3M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
PAVM
PAVmed, Inc.
|
-$72K | -$4.8M | 4.06% | 8.75% | -96880% | -$899K |
|
PDSB
PDS Biotechnology Corp.
|
-$15.1K | -$8.1M | -91.45% | -196.47% | -- | -$5.9M |
Cellectar Biosciences, Inc. vs. Competitors
-
Which has Higher Returns CLRB or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of 25.76%. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About CLRB or ACAD?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1446.05%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 32.03%. Given that Cellectar Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is CLRB or ACAD More Risky?
Cellectar Biosciences, Inc. has a beta of 0.323, which suggesting that the stock is 67.747% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock CLRB or ACAD?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or ACAD?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Cellectar Biosciences, Inc.'s net income of -$4.4M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 3.79x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M ACADACADIA Pharmaceuticals, Inc.3.79x 15.16x $278.6M $71.8M
-
Which has Higher Returns CLRB or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of 20.1%. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About CLRB or ALNY?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1446.05%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $479.79 which suggests that it could grow by 46.21%. Given that Cellectar Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 ALNYAlnylam Pharmaceuticals, Inc.13 8 0 -
Is CLRB or ALNY More Risky?
Cellectar Biosciences, Inc. has a beta of 0.323, which suggesting that the stock is 67.747% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock CLRB or ALNY?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or ALNY?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Cellectar Biosciences, Inc.'s net income of -$4.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,364.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 13.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M ALNYAlnylam Pharmaceuticals, Inc.13.46x 1,364.49x $1.2B $251.1M
-
Which has Higher Returns CLRB or IMNN?
Imunon, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of --. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About CLRB or IMNN?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1446.05%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 644.14%. Given that Cellectar Biosciences, Inc. has higher upside potential than Imunon, Inc., analysts believe Cellectar Biosciences, Inc. is more attractive than Imunon, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 IMNNImunon, Inc.3 1 0 -
Is CLRB or IMNN More Risky?
Cellectar Biosciences, Inc. has a beta of 0.323, which suggesting that the stock is 67.747% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock CLRB or IMNN?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or IMNN?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Cellectar Biosciences, Inc.'s net income of -$4.4M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns CLRB or PAVM?
PAVmed, Inc. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of -120220%. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat PAVmed, Inc.'s return on equity of 8.75%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M PAVMPAVmed, Inc.-1440% -$0.29 $35.1M -
What do Analysts Say About CLRB or PAVM?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1446.05%. On the other hand PAVmed, Inc. has an analysts' consensus of $9.50 which suggests that it could grow by 2538.89%. Given that PAVmed, Inc. has higher upside potential than Cellectar Biosciences, Inc., analysts believe PAVmed, Inc. is more attractive than Cellectar Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 PAVMPAVmed, Inc.1 0 0 -
Is CLRB or PAVM More Risky?
Cellectar Biosciences, Inc. has a beta of 0.323, which suggesting that the stock is 67.747% less volatile than S&P 500. In comparison PAVmed, Inc. has a beta of 1.118, suggesting its more volatile than the S&P 500 by 11.802%.
-
Which is a Better Dividend Stock CLRB or PAVM?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PAVmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. PAVmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or PAVM?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than PAVmed, Inc. quarterly revenues of $5K. Cellectar Biosciences, Inc.'s net income of -$4.4M is higher than PAVmed, Inc.'s net income of -$6M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while PAVmed, Inc.'s PE ratio is 0.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus 5,045.37x for PAVmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M PAVMPAVmed, Inc.5,045.37x 0.30x $5K -$6M
-
Which has Higher Returns CLRB or PDSB?
PDS Biotechnology Corp. has a net margin of -- compared to Cellectar Biosciences, Inc.'s net margin of --. Cellectar Biosciences, Inc.'s return on equity of -160.56% beat PDS Biotechnology Corp.'s return on equity of -196.47%.
Company Gross Margin Earnings Per Share Invested Capital CLRBCellectar Biosciences, Inc.-- -$1.41 $9.8M PDSBPDS Biotechnology Corp.-- -$0.19 $27.4M -
What do Analysts Say About CLRB or PDSB?
Cellectar Biosciences, Inc. has a consensus price target of $47.00, signalling upside risk potential of 1446.05%. On the other hand PDS Biotechnology Corp. has an analysts' consensus of $7.50 which suggests that it could grow by 948.95%. Given that Cellectar Biosciences, Inc. has higher upside potential than PDS Biotechnology Corp., analysts believe Cellectar Biosciences, Inc. is more attractive than PDS Biotechnology Corp..
Company Buy Ratings Hold Ratings Sell Ratings CLRBCellectar Biosciences, Inc.2 2 0 PDSBPDS Biotechnology Corp.3 0 0 -
Is CLRB or PDSB More Risky?
Cellectar Biosciences, Inc. has a beta of 0.323, which suggesting that the stock is 67.747% less volatile than S&P 500. In comparison PDS Biotechnology Corp. has a beta of 1.210, suggesting its more volatile than the S&P 500 by 21.023%.
-
Which is a Better Dividend Stock CLRB or PDSB?
Cellectar Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PDS Biotechnology Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cellectar Biosciences, Inc. pays -- of its earnings as a dividend. PDS Biotechnology Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CLRB or PDSB?
Cellectar Biosciences, Inc. quarterly revenues are --, which are smaller than PDS Biotechnology Corp. quarterly revenues of --. Cellectar Biosciences, Inc.'s net income of -$4.4M is higher than PDS Biotechnology Corp.'s net income of -$9M. Notably, Cellectar Biosciences, Inc.'s price-to-earnings ratio is -- while PDS Biotechnology Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cellectar Biosciences, Inc. is 137.94x versus -- for PDS Biotechnology Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CLRBCellectar Biosciences, Inc.137.94x -- -- -$4.4M PDSBPDS Biotechnology Corp.-- -- -- -$9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
53
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 30x
Alerts
Sell
40
BILL alert for Feb 9
Bill Holdings, Inc. [BILL] is up 3.7% over the past day.
Buy
75
PRLB alert for Feb 9
Proto Labs, Inc. [PRLB] is down 2.16% over the past day.
Sell
30
MSTR alert for Feb 9
Strategy, Inc. [MSTR] is up 2.59% over the past day.
